Skip to main content
Download PDF
- Main
Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
- Allan, John N;
- Siddiqi, Tanya;
- Kipps, Thomas J;
- Kuss, Bryone J;
- Badoux, Xavier C;
- Barrientos, Jacqueline C;
- Tedeschi, Alessandra;
- Opat, Stephen;
- Flinn, Ian W;
- Barca, Eva Gonzalez;
- Jacobs, Ryan;
- Szafer-Glusman, Edith;
- Zhou, Cathy;
- Szoke, Anita;
- Wierda, William G;
- Ghia, Paolo;
- Tam, Constantine S
Published Web Location
https://doi.org/10.1182/blood-2022-160338Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.